Lipid-Layer Interferometry

The outermost region of the tear film is rich in lipids. Most of these lipids originate from meibum, the secretion produced by the meibomian glands. After meibum reaches the eyelid margin, blinking helps distribute it across the tear surface.

The resulting lipid layer is extraordinarily thin. But it is not simply a fixed sheet of oil floating on top of water. It is a dynamic structure whose composition, organization, distribution, thickness and interaction with the rest of the tear film can all matter.

Interferometry uses the way light reflects from extremely thin surfaces. When light reaches the tear film, reflections occur at different interfaces within the lipid-rich surface region. Those reflected light waves interact with one another and create characteristic interference patterns.

These patterns can appear as different colors, textures or shapes. By analyzing them, an instrument can estimate properties of the tear-film lipid layer, including its thickness. And it can do this without touching the eye.

Lipid-layer thickness — usually abbreviated LLT — is an estimate of how thick the lipid-rich region of the tear film appears to be. Some devices provide a numerical estimate. Others classify the interference pattern into grades that correspond approximately to different thicknesses. This can be useful information. For example, lipid-layer thickness has been associated in studies with:

• •meibomian gland expressibility
• •meibomian gland loss
• •tear-film breakup time
• •MGD severity
• •blink patterns

But these are associations. They do not mean that LLT is a direct measurement of all of these things.

Not automatically. A reduced lipid-layer thickness can occur with obstructive MGD, where less meibum reaches the tear-film surface. So a thin lipid layer can certainly be an important clue.

But interferometry is examining the tear film, not looking inside the meibomian glands. If the lipid layer appears thin, the next question is why. To investigate that, we may need to look at meibum expressibility, meibum quality, gland openings, lid-margin findings, meibography and blinking.

So a thin lipid layer is not an MGD diagnosis. It is a tear-film finding that may help point us toward a possible mechanism.

No. This is just as important as understanding a thin result.

A relatively thick lipid layer does not automatically mean that the meibomian glands are functioning normally. For example, TFOS DEWS III notes that lipid-layer thickness may actually be increased in hypersecretory MGD.

So more lipid is not automatically better lipid function. A high LLT value should not simply be interpreted as “My oil layer is excellent.” The wider gland and tear-film picture still matters.

This is probably the most important misconception surrounding lipid-layer interferometry.

It sounds logical: more oil → better seal → less water escapes. But the evidence does not support such a simple relationship.

TFOS DEWS III specifically states that a direct association between lipid-layer thickness and tear evaporation rate has not been proven. Studies examining this relationship have produced inconsistent results.

That means we should not automatically translate a thin lipid layer into high evaporation, or a thick lipid layer into good protection from evaporation. Thickness is only one property of the lipid layer.

Because the function of the tear-film lipid layer may depend on more than how thick it is. Its composition, organization, uniformity, distribution across the eye and dynamic behaviour between blinks may all matter.

Two lipid layers with similar average thickness may not necessarily behave in exactly the same way. And a thicker layer may not necessarily be evenly organized or distributed.

This is one reason modern research is moving beyond the idea that the lipid layer is simply a thicker-or-thinner oil barrier.

No. Interferometry measures properties of the lipid layer. Evaporation is a different physiological process. There are specialized research techniques designed to measure tear evaporation directly, but ordinary lipid-layer interferometry is not one of them.

This distinction matters. If your LLT is low, your report has not directly measured “how fast my tears evaporate.” It has measured a property of the tear-film lipid component that may be related to tear-film behaviour.

Yes. A 2025 review of lipid-layer thickness research found substantial overlap between LLT measurements in healthy individuals and people with dry eye. Reported values also vary considerably depending on the instrument and method used.

This means there is no simple LLT number that cleanly separates healthy from dry eye. A person can therefore have dry eye with an LLT measurement that does not appear particularly low. That is one reason lipid-layer thickness should not be used by itself to diagnose dry eye disease.

Yes. Again, there is substantial overlap between populations. The 2025 review found a very wide range of reported lipid-layer thicknesses even among healthy individuals, partly because different instruments and grading systems measure the lipid layer differently. So one number should not be interpreted without knowing which device measured it, how it was calculated, and what the rest of the examination showed.

Yes. Different interferometry systems do not necessarily measure or report lipid-layer thickness in exactly the same way. Some provide numerical thickness estimates. Some rely on grading interference patterns. Different instruments may examine different areas of the tear film and use different algorithms.

A recent review concluded that lipid-layer thickness measurements from different technologies are not necessarily interchangeable.

This is similar to the problem we discussed with meibography. A number printed by a machine may look extremely precise. But the method used to generate that number matters.

The colors seen during interferometry are created by optical interference. They are not literal colors of the meibum. The instrument uses the pattern created by reflected light to infer characteristics of the thin lipid layer.

So a colorful interferometry image should not be interpreted as a photograph showing different colored types of oil sitting on the eye. It is an optical pattern produced by the way light interacts with the tear-film surface.

The lipid layer is dynamic. Each blink helps redistribute meibum across the tear film. That means the lipid pattern seen immediately after blinking may change as the eye remains open.

Blink completeness can also matter. If the eyelids do not close fully during a blink, meibum may not be distributed across the ocular surface normally.

So when interpreting interferometry, it can be useful to consider how often the person is blinking, whether the blinks are complete, and how the lipid pattern changes after a blink. Some instruments can observe these dynamics rather than providing only a single static measurement.

Not directly. This is another important distinction. Interferometry asks what the lipid component of the tear film looks like at the ocular surface. Meibomian gland expression asks what secretion can be obtained from the glands. Meibography asks what the glands look like structurally. These three tests examine different stages of the system:

gland structure→gland secretion→lipid behaviour in the tear film

They are connected. But they are not interchangeable.

That is possible. Meibum being expressible from the glands does not automatically guarantee that the final lipid layer will immediately have a particular thickness or pattern.

After secretion reaches the lid margin, it still has to be distributed across the eye. Blinking matters. The properties of the meibum matter. The rest of the tear film matters. And the interferometry measurement itself has limitations.

This is why apparently conflicting test results do not necessarily mean that one test must be wrong. They may simply be measuring different parts of the system.

Not by itself. Lipid-layer thickness may correlate with some measures of MGD. But there is substantial overlap between individuals. MGD assessment may also include meibum expressibility, meibum quality, gland openings, lid-margin findings and meibography. So an LLT number should not become a standalone MGD severity score.

Not by itself. TFOS DEWS III recognizes lipid interferometry as useful when identifying lipid deficiency as a possible etiological driver. But it is not one of the core tests used by itself to establish the general diagnosis of dry eye disease. A large recent review likewise concluded that the substantial overlap in LLT between healthy people and patients with dry eye prevents lipid-layer thickness from serving as a standalone diagnostic test.

It can provide information about:

• •the appearance and distribution of the tear-film lipid layer
• •its interference pattern
• •an estimate of lipid-layer thickness
• •with some systems, how the lipid layer changes with blinking

This can help clinicians investigate whether abnormalities of the lipid component may be contributing to the dry-eye picture.

By itself, interferometry cannot tell you:

• •whether you have MGD
• •whether your meibomian glands are structurally healthy
• •exactly how much meibum they produce
• •how quickly your tears evaporate
• •whether a thicker lipid layer is functioning better than a thinner one
• •whether you have dry eye disease

Those questions require other information.